What do we know about the transmission of herpes and treatment options for herpes? Antiviral suppression? What about catamenial occurrences? Join us as we explore the subject with Dr Peter Greenhouse.

The audio from this podcast came from an EADV Webcast titled: 

EADV Members can access the whole webcast at here.

Not an EADV Member? Click Here for more information on the advantages and opportunities that only EADV Members have- including access to webcasts such as this one.

This week Prof. Christos Zouboulis from the Dessau Medical Center interviews Bente Villumsen, the President of the Patientforeningen HS Danmark (Danish Hidradenitis Suppurativa Patient Association). They discuss the importance of increasing disease awareness, availability of reliable medical information incorporating the patient perspective and establishing a meaningful cooperation between patients, their treating dermatologists as well as the industry. 

Not an EADV Member? Click Here for more information on the advantages and opportunites that only EADV Members have.

Join us as we go through the JEADV Editor's Picks of January 2022:

(1) Dermatologic origin of a fatal C. ciferrii systemic infection

This week JEADV Clinical Practice Editor-in-Chief Dr. Antonio Torrelo talks about his three decades of experience in Paediatrics Dermatology, highlighting the most important skills and challenges of treating children with skin diseases. Moreover, Dr. Torrelo shares some key facts about JEACP and reveals how a day in the life of the Editor of EADV's new Open Access journal looks like.

This week Prof. Ashraf Badawi covers more topics connected with challenging situations in cosmetic dermatology. In this second episode of a two-part- series he discusses laser and light-based therapies and injectables in autoimmune diseases, particularly Lupus and considers how to, and when not to, treat patients with psychological disorders seeking aesthetic procedures. He brings practical clinical experience as well as the current research to the discussion. 

Not an EADV Member? Click Here for more information on the advantages and opportunities that only EADV Members have- including access to webcasts such as this one.

Join us as we go through the JEADV Editor's Picks of December 2021:

Could better understanding of the role of autoantibodies hold the key to personalised treatments in itchy and blistering diseases?

This week we bring together experts Prof. Kridin and Dr. Meijer to discuss their recent JEADV publications concerning the role of autoantibodies in itchy and blistering diseases. Prof. Kridin talks about the pathophysiology and therapeutic approaches to treat patients with bullous pemphigoid and comorbid psoriasis, followed by Dr. Meijer’s explanation regarding the role of IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients.

References

https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.16996

Not an EADV Member? Click Here for more information on the advantages and opportunites that only EADV Members have.

Should you stop an anticoagulant for thrombosis to prevent bruising after cosmetic procedures? What changed during the pandemic? Can ablative laser plumes harm operating room personnel?

This week Prof. Ashraf Badawi discusses challenging situations that can arise in cosmetic dermatology. He brings practical clinical experience as well as the current research to the discussion.

Not an EADV Member? Click Here for more information on the advantages and opportunities that only EADV Members have- including access to webcasts such as this one.

Join us as we go through the JEADV Editor's Picks of November 2021:

Read the editor's picks here:

https://onlinelibrary.wiley.com/doi/10.1111/jdv.17691

This week EADV Advocacy Working Group Leader Myrto Trakatelli talks with Stella Siskou about topics including EPIDERM, the EADV Advocacy Working Group, and a position paper on the role of dermatologists in the evolving field of Dermato-oncology.

The evolving field of Dermato-oncology and the role of dermatologists: Position Paper of the EADO, EADV and Task Forces, EDF, IDS, EBDV–UEMS and EORTC Cutaneous Lymphoma Task Force